SAB Biotherapeutics Constructs Production Facility

Published 9-25-2017

SAB Biotherapeutics began construction in August of 2017 on an agricultural production facility for antibody therapeutics. The 80-acre ‘pharm’ will accommodate transgenic cattle which produce plasma in reaction to a vaccine, providing a source of natural human polyclonal antibodies. The facility is located adjacent to SAB’s existing corporate headquarters and is slated for completion in spring of 2018.